(Q43705777)

26 November 2017

title

Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in healthy Chilean subjects (English)

1 reference

26 November 2017

0 references

1 reference

V Prado

1

1 reference

26 November 2017

S Riedemann

series ordinal

2

1 reference

26 November 2017

H Ibarra

series ordinal

3

1 reference

26 November 2017

M Potin

series ordinal

4

1 reference

26 November 2017

publication date

1 June 2002

1 reference

International Journal of Infectious Diseases

26 November 2017

published in

1 reference

26 November 2017

volume

6

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

129-133

1 reference

Hepatitis A in Latin America: a changing epidemiologic pattern

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Hepatitis B seroprevalence in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Hepatitis B epidemiology in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Cost-benefit analysis of hepatitis-B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Clinical trial with inactivated hepatitis A vaccine and recommendations for its use

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

1 reference

7 January 2021

Hepatitis A shifting epidemiology in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Hepatitis B virus infection in hospital staff: epidemiology and persistence of vaccine-induced antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Prevalence of antibodies to hepatitis A virus in health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Increased risk for hepatitis A among female day nursery workers in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Risk factors for hepatitis A in day-care centers

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

HBV infection in hemodialysis patients: monitoring and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

The first combined vaccine against hepatitis A and B: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990074-3

7 January 2021

10.1016/S1201-9712(02)90074-3

Identifiers

DOI

1 reference

26 November 2017

1 reference